{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:01:23Z","timestamp":1780635683269,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004360","name":"Swedish University of Agricultural Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004360","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir Vet J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cannabidiol (CBD) and cannabidiolic acid (CBDA) are non-psychoactive cannabinoids naturally present in hemp-derived products. While these compounds are prohibited during equine competition, horses may be inadvertently exposed through contaminated feed. Data describing systemic and urinary exposure to CBD and CBDA following such low-dose, involuntary intake are limited. This study aimed to describe plasma and urine concentration-time profiles of CBD and CBDA in horses after consumption of experimentally contaminated feed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twelve Standardbred horses received feed containing low doses (10\u201315\u00a0mg) of either CBD or CBDA twice daily for three days. Neither compound was detected in pre-administration samples. Following exposure, CBD was only sporadically quantifiable in plasma, whereas CBDA was detected in plasma from most horses for up to 48\u00a0h. In urine, both cannabinoids were quantifiable in all horses, with CBDA consistently present at higher concentrations and for longer durations than CBD. Maximum observed urinary concentrations were markedly higher for CBDA than for CBD. Considerable inter-individual variability was observed in both plasma and urine concentrations. Neither CBD nor CBDA was detected in plasma or urine for more than four days. Overall, systemic exposure following feed contamination was low compared with doses reported to produce therapeutic effects in horses or other species.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Low-dose oral exposure to CBD and CBDA, mimicking feed contamination, can result in detectable concentrations of cannabinoids in equine plasma and urine, with CBDA representing the predominant analyte. Although the study was not designed to establish detection times and analytical sensitivity may differ from routine doping control, the findings demonstrate that inadvertent exposure through feed may lead to measurable cannabinoid concentrations despite doses well below those associated with reported pharmacological effects. These results highlight the importance of awareness of potential contamination sources and cautious interpretation of low-level cannabinoid findings in equine biological samples.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13620-026-00350-6","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:34:51Z","timestamp":1780544091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma and urinary exposure of cannabidiol and cannabidiolic acid in horses following consumption of contaminated feed"],"prefix":"10.1186","volume":"79","author":[{"given":"Carl","family":"Ekstrand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Michanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Hernlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronette","family":"Gehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda","family":"Salomonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"11","key":"350_CR1","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrn3811","volume":"15","author":"R Mechoulam","year":"2014","unstructured":"Mechoulam R, Hanu\u0161 LO, Pertwee R, Howlett AC. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci. 2014;15(11):757\u201364. https:\/\/doi.org\/10.1038\/nrn3811.","journal-title":"Nat Rev Neurosci"},{"key":"350_CR2","doi-asserted-by":"publisher","unstructured":"De Briyne N, Holmes D, Sandler I, Stiles E, Szymanski D, Moody S, et al. Cannabis, cannabidiol oils and tetrahydrocannabinol\u2014what do veterinarians need to know? Anim (Basel). 2021;11(3). https:\/\/doi.org\/10.3390\/ani11030892.","DOI":"10.3390\/ani11030892"},{"key":"350_CR3","doi-asserted-by":"publisher","first-page":"1496473","DOI":"10.3389\/fvets.2024.1496473","volume":"11","author":"F Aragona","year":"2024","unstructured":"Aragona F, Tabb\u00ec M, Gugliandolo E, Giannetto C, D\u2019Angelo F, Fazio F, et al. Role of cannabidiolic acid or the combination of cannabigerol\/cannabidiol in pain modulation and welfare improvement in horses with chronic osteoarthritis. Front Vet Sci. 2024;11:1496473. https:\/\/doi.org\/10.3389\/fvets.2024.1496473.","journal-title":"Front Vet Sci"},{"key":"350_CR4","doi-asserted-by":"publisher","first-page":"1341396","DOI":"10.3389\/fvets.2024.1341396","volume":"11","author":"C Interlandi","year":"2024","unstructured":"Interlandi C, Tabb\u00ec M, Di Pietro S, D\u2019Angelo F, Costa GL, Arfuso F, et al. Improved quality of life and pain relief in mature horses with osteoarthritis after oral transmucosal cannabidiol oil administration as part of an analgesic regimen. Front Vet Sci. 2024;11:1341396. https:\/\/doi.org\/10.3389\/fvets.2024.1341396.","journal-title":"Front Vet Sci"},{"key":"350_CR5","doi-asserted-by":"publisher","unstructured":"Toutain PL. Veterinary medicines and competition animals: the question of medication versus doping control. Handb Exp Pharmacol. 2010;199315\u201339. https:\/\/doi.org\/10.1007\/978-3-642-10324-7_13.","DOI":"10.1007\/978-3-642-10324-7_13"},{"issue":"1","key":"350_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tvjl.2014.01.006","volume":"200","author":"JK Wong","year":"2014","unstructured":"Wong JK, Wan TS. Doping control analyses in horseracing: a clinician\u2019s guide. Vet J. 2014;200(1):8\u201316. https:\/\/doi.org\/10.1016\/j.tvjl.2014.01.006.","journal-title":"Vet J"},{"key":"350_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3783","author":"S Trevisiol","year":"2024","unstructured":"Trevisiol S, Popot MA, Garcia P, Boyer S, Caroff M, Drif L, et al. In vivo comparative study of hemp straw exposure and cannabidiol oil administration in horse urine. Drug Test Anal. 2024. https:\/\/doi.org\/10.1002\/dta.3783.","journal-title":"Drug Test Anal"},{"issue":"1","key":"350_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/jvp.70027","volume":"49","author":"C Ekstrand","year":"2026","unstructured":"Ekstrand C, Michanek P, Hernlund E, Gehring R, Spjut K, Salomonsson M. Differences in plasma exposure of cannabidiol and cannabidiolic acid following oral administration to horses. J Vet Pharmacol Ther. 2026;49(1):22\u201332. https:\/\/doi.org\/10.1111\/jvp.70027.","journal-title":"J Vet Pharmacol Ther"},{"key":"350_CR9","doi-asserted-by":"publisher","first-page":"1356463","DOI":"10.3389\/fvets.2024.1356463","volume":"11","author":"ACS Thomson","year":"2024","unstructured":"Thomson ACS, McCarrel TM, Zakharov A, Gomez B, Lyubimov A, Schwark WS, et al. Pharmacokinetics and tolerability of single-dose enteral cannabidiol and cannabidiolic acid rich hemp in horses (Equus caballus). Front Vet Sci. 2024;11:1356463. https:\/\/doi.org\/10.3389\/fvets.2024.1356463.","journal-title":"Front Vet Sci"},{"key":"350_CR10","doi-asserted-by":"publisher","unstructured":"Wang TC, Wakshlag JJ, Jager MC, Schwark WS, Trottier NL, Chevalier JM, et al. Chronic oral dosing of cannabidiol and cannabidiolic acid full-spectrum hemp oil extracts has no adverse effects in horses: a pharmacokinetic and safety study. Am J Vet Res. 2025;1\u201310. https:\/\/doi.org\/10.2460\/ajvr.24.08.0235.","DOI":"10.2460\/ajvr.24.08.0235"},{"key":"350_CR11","doi-asserted-by":"publisher","unstructured":"Sosa-Higareda M, Guzman DS, Knych H, Lyubimov A, Zakharov A, Gomez B, et al. Twice-daily oral administration of a cannabidiol and cannabidiolic acid-rich hemp extract was well tolerated in orange-winged Amazon parrots (Amazona amazonica) and has a favorable pharmacokinetic profile. Am J Vet Res. 2023;84(4). https:\/\/doi.org\/10.2460\/ajvr.22.11.0197.","DOI":"10.2460\/ajvr.22.11.0197"},{"key":"350_CR12","doi-asserted-by":"publisher","first-page":"100289","DOI":"10.1016\/j.vas.2023.100289","volume":"19","author":"RZ Cunha","year":"2023","unstructured":"Cunha RZ, Felisardo LL, Salamanca G, Marchioni GG, Neto OI, Chiocchetti R. The use of cannabidiol as a novel treatment for oral stereotypic behaviour (crib-biting) in a horse. Vet Anim Sci. 2023;19:100289. https:\/\/doi.org\/10.1016\/j.vas.2023.100289.","journal-title":"Vet Anim Sci"},{"issue":"4","key":"350_CR13","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/eve.13168","volume":"33","author":"KL Ellis","year":"2021","unstructured":"Ellis KL, Contino EK. Treatment using cannabidiol in a horse with mechanical allodynia. Equine Vet Educ. 2021;33(4):e79\u201382. https:\/\/doi.org\/10.1111\/eve.13168.","journal-title":"Equine Vet Educ"},{"key":"350_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3389\/fvets.2018.00165","volume":"5","author":"LJ Gamble","year":"2018","unstructured":"Gamble LJ, Boesch JM, Frye CW, Schwark WS, Mann S, Wolfe L, et al. Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Front Vet Sci. 2018;5:165. https:\/\/doi.org\/10.3389\/fvets.2018.00165.","journal-title":"Front Vet Sci"},{"issue":"1","key":"350_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s42238-025-00322-7","volume":"7","author":"JD McDonald","year":"2025","unstructured":"McDonald JD, Zhou F, Kulpa J, Kuehl PJ. Preclinical assessment of pharmacokinetics and anticonvulsant activity of CBDTech, a novel orally administered cannabidiol (CBD) formulation for seizure and epilepsy. J Cannabis Res. 2025;7(1):73. https:\/\/doi.org\/10.1186\/s42238-025-00322-7.","journal-title":"J Cannabis Res"},{"issue":"3","key":"350_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2746\/042516402776185985","volume":"34","author":"PL Toutain","year":"2002","unstructured":"Toutain PL. Veterinary medicines and competition animals: the question of medication versus doping control. Handb Exp Pharmacol. 2010:(199):315\u201339. https:\/\/doi.org\/10.1007\/978-3-642-10324-7_1m.","journal-title":"Equine Vet J"},{"issue":"3","key":"350_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2746\/042516402776185985","volume":"34","author":"PL Toutain","year":"2002","unstructured":"Toutain PL, Lassourd V. Pharmacokinetic\/pharmacodynamic approach to assess irrelevant plasma or urine drug concentrations in postcompetition samples for drug control in the horse. Equine Vet J. 2002;34(3):242\u2013918.","journal-title":"Equine Vet J"},{"issue":"3","key":"350_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.2042-3306.2010.00028.x","volume":"42","author":"PL Toutain","year":"2010","unstructured":"Toutain PL. How to extrapolate a withdrawal time from an EHSLC published detection time: a Monte Carlo simulation appraisal. Equine Vet J. 2010;42(3):248\u201354. https:\/\/doi.org\/10.1111\/j.2042-3306.2010.00028.x.","journal-title":"Equine Vet J"},{"key":"350_CR19","doi-asserted-by":"publisher","first-page":"1234551","DOI":"10.3389\/fvets.2023.1234551","volume":"10","author":"F Eichler","year":"2023","unstructured":"Eichler F, Po\u017aniak B, Machnik M, Schenk I, Wingender A, Baudisch N, et al. Pharmacokinetic modelling of orally administered cannabidiol and implications for medication control in horses. Front Vet Sci. 2023;10:1234551. https:\/\/doi.org\/10.3389\/fvets.2023.1234551.","journal-title":"Front Vet Sci"},{"issue":"7","key":"350_CR20","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/dta.3028","volume":"13","author":"D Ryan","year":"2021","unstructured":"Ryan D, McKemie DS, Kass PH, Puschner B, Knych HK. Pharmacokinetics and effects on arachidonic acid metabolism of low doses of cannabidiol following oral administration to horses. Drug Test Anal. 2021;13(7):1305\u201317. https:\/\/doi.org\/10.1002\/dta.3028.","journal-title":"Drug Test Anal"}],"container-title":["Irish Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13620-026-00350-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13620-026-00350-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13620-026-00350-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:21:27Z","timestamp":1780633287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13620-026-00350-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["350"],"URL":"https:\/\/doi.org\/10.1186\/s13620-026-00350-6","relation":{},"ISSN":["2046-0481"],"issn-type":[{"value":"2046-0481","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Animal Ethics Committee, Uppsala, Sweden (5.8.18\u201302809\/2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CE is a pharmacological advisor to the Swedish Trotting Association. Other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}